KMT2A and acute myeloid leukemia: Several studies have shown that allo-HSCT is a curative option and is beneficial in paediatric MLL-r AML, especially in the poor prognosis subgroups with MLL-ALL1-fused gene from chromosome 6 (MLL-AF6) or MLL-AF10 [6, 11].